Deutsche Bank’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $451K | Sell |
22,475
-5,049
| -18% | -$101K | ﹤0.01% | 2500 |
|
|
2025
Q1 | $542K | Sell |
27,524
-2,992
| -10% | -$58.9K | ﹤0.01% | 2427 |
|
|
2024
Q4 | $687K | Buy |
30,516
+10,397
| +52% | +$234K | ﹤0.01% | 2425 |
|
|
2024
Q3 | $514K | Buy |
20,119
+4,868
| +32% | +$124K | ﹤0.01% | 2402 |
|
|
2024
Q2 | $356K | Buy |
15,251
+4,277
| +39% | +$100K | ﹤0.01% | 2484 |
|
|
2024
Q1 | $193K | Buy |
10,974
+343
| +3% | +$6.03K | ﹤0.01% | 2798 |
|
|
2023
Q4 | $147K | Sell |
10,631
-259
| -2% | -$3.59K | ﹤0.01% | 2987 |
|
|
2023
Q3 | $149K | Buy |
10,890
+1,559
| +17% | +$21.3K | ﹤0.01% | 2937 |
|
|
2023
Q2 | $190K | Buy |
+9,331
| New | +$190K | ﹤0.01% | 2901 |
|
|
2021
Q4 | – | Sell |
-25
| Closed | – | – | 4079 |
|
|
2021
Q3 | $0 | Sell |
25
-5,351
| -100% | – | ﹤0.01% | 4263 |
|
|
2021
Q2 | $170K | Buy |
5,376
+2,531
| +89% | +$80K | ﹤0.01% | 3823 |
|
|
2021
Q1 | $96K | Buy |
2,845
+1,439
| +102% | +$48.6K | ﹤0.01% | 3927 |
|
|
2020
Q4 | $124K | Buy |
1,406
+714
| +103% | +$63K | ﹤0.01% | 3654 |
|
|
2020
Q3 | $56K | Buy |
692
+60
| +9% | +$4.86K | ﹤0.01% | 3770 |
|
|
2020
Q2 | $70K | Buy |
+632
| New | +$70K | ﹤0.01% | 3582 |
|